* Aprea Therapeutics Inc APRE.OQ APRE.O is expected
to show no
change in quarterly revenue when it reports results on November
7 (estimated).
*
* Refinitiv's mean analyst estimate for Aprea Therapeutics
Inc is
for a loss of 28 cents per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Aprea
Therapeutics Inc is $3, above its last closing price of $0.69.
This summary was machine generated November 4 at 14:33 GMT. All
figures in US dollars unless otherwise stated